
🎉 Introducing Targeted Onc! New name. New look. Same focus. 💜 Targeted Oncology™ is now Targeted Onc, continuing our mission to connect science to practice and deliver actionable insights for community oncologists. Explore: hubs.li/Q04CB_950
✓Connecting community oncology with emerging science, actionable insights & peer perspectives to advance patient care.

🎉 Introducing Targeted Onc! New name. New look. Same focus. 💜 Targeted Oncology™ is now Targeted Onc, continuing our mission to connect science to practice and deliver actionable insights for community oncologists. Explore: hubs.li/Q04CB_950

The #FDA is reviewing selinexor + ruxolitinib as a potential first combination therapy for #Myelofibrosis Phase 3 SENTRY data showed improved spleen volume reduction vs ruxolitinib alone. 🔬 Read more: tinyurl.com/3p7v4879 #Hematology #FDAnews

Treatment selection in recurrent diffuse TGCT involves balancing efficacy, adverse effects, and monitoring demands. Richard F. Riedel, MD, shares insights from a Case-Based Roundtable. Explore the discussion: tinyurl.com/4zwjyxyr

🔎 🚨FDA APPROVAL: The #FDA granted accelerated approval to neladalkib (NelkarmI) for ALK+ #NSCLC, indicated in second line after alectinib or after2 prior ALK TKIs and platinum-based chemotherapy. Read more: targetedonc.com/view/neladal…

🧬 The @FDA has granted fast track designation to investigational onvansertib + FOLFIRI/bevacizumab for first-line #RAS-mutated mCRC. Phase 2 CRDF-004 data showed a 72.2% ORR. Read more: tinyurl.com/3wy6jvxm #ColorectalCancer #Oncology

With no standard second-line option for platinum-refractory thymic carcinoma, final PECATI results in @IASLC @JTOonline support lenvatinib plus pembrolizumab as a potential choice, though investigators cautioned of need for monitoring. 🔗 targetedonc.com/view/lenvati…

On Targeted Talks: Dr Jennifer Ligibel, @DFCI_BreastOnc, discusses quality-of-life data from the phase 3 BWEL trial, plus insurance barriers and where GLP-1s fit for patients with breast cancer. 🔈 Listen: targetedonc.com/view/targete…

🔬 Updated LEGEND trial data show durable responses with detalimogene in BCG-unresponsive #NMIBC, supporting a planned BLA submission by year-end 2026. Read more: targetedonc.com/view/detalim… #BladderCancer #Oncology #CancerTreatment

🚨The FDA has approved giredestrant (Wilserdly) plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. In evERA, median PFS was 10 vs 5.5 months (HR, 0.38). targetedonc.com/view/giredes…

A new biosimilar option for HER2-positive breast cancer: Biocon's pertuzumab-qcay (Pebrilzo) received @FDA approval, with US availability expected in 2028. Read More -> tinyurl.com/mvpw6epb #Oncology #BreastCancer

🧬 How should clinicians approach treatment after CDK4/6 inhibitor progression in HR+/HER2− breast cancer? Prakash Peddi, MD, discusses ctDNA testing, ESR1 alterations, and treatment selection. Read: tinyurl.com/2mr8wnu3 #BreastCancer #Oncology #HRPositive #CDK46

🧬 PANOVA-3 findings show tumor treating fields improved pain and quality-of-life outcomes in locally advanced pancreatic cancer. READ: tinyurl.com/mpp53mh6 #PancreaticCancer #Oncology #TTFields @JAMANetworkOpen

🔬PIVOT-006 topline data show an 68% reduction in recurrence risk for cretostimogene vs surveillance in intermediate-risk #NMIBC; RFS rates and subgroup data await the #SUO2026 presentation on December 2. A BLA is planned for Q2 2027. 🔗 targetedonc.com/view/cretost… #bladdercancer

"We're not interested in bringing patients to academic centers and keeping them there." @marklewismd on when community oncologists should loop in a NET specialist, and why it doesn't mean losing your patient. 🎥 targetedonc.com/view/neuroen… #NANETS2026 #NETCancer @NANETS1

RLT, cabozantinib, or everolimus first? There’s no randomized answer yet. Dr Arvind Dasari (@MDAndersonNews) shares how he weighs SSTR status, tumor bulk, Ki-67, comorbidities, and patient preference in NETs. @nanets1 @NANETS2026 targetedonc.com/view/dr-dasa…

🚨The FDA has rejected ivonescimab plus chemotherapy in EGFR-mutated #NSCLC, citing the lack of a statistically significant OS benefit in HARMONi. #LCSM #FDA targetedonc.com/view/fda-doe…